Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
Chinese Patent Office
UBS
McKesson
Citi
Fish and Richardson
Medtronic
Harvard Business School
Accenture

Generated: August 18, 2017

DrugPatentWatch Database Preview

KANTREX Drug Profile

« Back to Dashboard

Which patents cover Kantrex, and when can generic versions of Kantrex launch?

Kantrex is a drug marketed by Apothecon and is included in six NDAs.

The generic ingredient in KANTREX is kanamycin sulfate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the kanamycin sulfate profile page.

Summary for Tradename: KANTREX

Patents:0
Applicants:1
NDAs:6
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:KANTREX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apothecon
KANTREX
kanamycin sulfate
INJECTABLE;INJECTION061901-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
KANTREX
kanamycin sulfate
INJECTABLE;INJECTION061655-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
KANTREX
kanamycin sulfate
CAPSULE;ORAL061911-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
KANTREX
kanamycin sulfate
INJECTABLE;INJECTION062564-002Sep 21, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Apothecon
KANTREX
kanamycin sulfate
INJECTABLE;INJECTION061655-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Boehringer Ingelheim
Dow
Deloitte
Fish and Richardson
Daiichi Sankyo
Harvard Business School
McKesson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot